Vitamin D levels in oesophageal and gastric cancer patients and their outcome

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. Thanthulage
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors S. Thanthulage, V. Jayanthi, S. Kadirkamanathan, C.-. Tang
  • Broomfield Hospital, Chelmsford, United Kingdom, /

Abstract

The association of vitamin D deficiency with many chronic diseases worldwide is well known. Nevertheless, it has not been convincingly shown in randomised controlled trials that diseases can be controlled or prevented by having optimum or higher vitamin D levels. The available experimental data on vitamin D and its metabolites suggest that it has beneficial effects on the prevention or treatment of various cancers and other diseases. Many investigations of the aetiopathogenesis and treatment of upper GI malignancies have been performed, but investigations of the vitamin D and treatment of deficiency in cancer patients is not a priority. This may be due to the lack of convincing evidence despite many snap shot observational vitamin D trials in patients with upper GI cancers that have yielded conflicting results. Therefore the impact of vitamin D on the survival or patients' quality of life remains unclear. However, there have been a few observational trials that support the positive correlation of vitamin D levels and the survival of colorectal cancer patients.